WASHINGTON — Commissioner Marty Makary wants the Food and Drug Administration to move more quickly. The launch of a new priority review voucher program in June was no exception.

The agency promised winners a one- to two-month review of their drug applications, and speedy reviewer feedback. Interested companies had to prove they aligned with one of several national health priorities, which included addressing a public health crisis, delivering more innovative cures, addressing an unmet medical need, bringing drug manufacturing to the United States, and increasing affordability.

“We got a tremendous amount of interest nationwide,” Makary told FDA drug regulators at an internal meeting in August. “We didn’t expect the incredible interest we got. The second we announced it, we had people s

See Full Page